Werewolf Therapeutics agrees to merge with Ambros Therapeutics in all-stock deal

The transaction is paired with an oversubscribed $150 million private placement, set to close concurrently with the merger.

The financing is expected to fund operations through CRPS-RISE Phase 3 topline results in 2028, planned NDA filing, and a cash runway into 1H 2029.

Neridronate holds FDA Breakthrough Therapy, Fast Track and Orphan Drug designations; FDA alignment suggests one successful Phase 3 trial could support approval.

Werewolf Therapeutics agreed to an all-stock merger with Ambros Therapeutics, creating a Nasdaq-listed company focused on neridronate for CRPS-1.

The combined company is expected to operate as Ambros Therapeutics, headquartered in San Diego, and trade under ticker AMBX.